000			04956cam a2200517 i 4500
001			on1268332849
003			OCoLC
005			20250508013043.0
006			m d
007			cr cnu|||unuuu
008			210917s2021 enk o 000 0 eng d
040			_aN$T _beng _erda _epn _cN$T _dEBLCP _dOCLCO _dOCLCF _dYT1 _dOCLCO _dOCLCQ _dOCLCO _dOCLCL _dUKOBU
019			_a1267760905
020			_a9781914171451 _q(electronic bk.)
020			_a1914171454 _q(electronic bk.)
020			_z9781914171444
035			_a3028130 _b(N$T)
035			_a(OCoLC)1268332849 _z(OCoLC)1267760905
050		4	_aRM315
082	0	4	_a615.78 _223
049			_aMAIN
100	1		_aMwebe, Herbert, _eauthor _1https://id.oclc.org/worldcat/entity/E39PCjKPbVpc9tYvyPVFMFRc4C
245	1	0	_aPsychopharmacology : _ba mental health professional's guide to commonly used medications / _cHerbert Mwebe.
250			_aSecond edition
264		1	_aSt. Albans: _bCritical Publishing, _c2021.
300			_a1 online resource (xiii, 314 pages)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
490	1		_aNursing
588	0		_aVendor-supplied metadata.
504			_aIncludes bibliographical references and index.
505	0		_aCover -- Title page -- Copyright information -- Table of contents -- Meet the author -- Acknowledgements -- Foreword -- Praise for the first edition -- Introduction -- The structure of this book -- Learning features -- 1 Mental illness -- 1.1 Introduction -- 1.2 Aetiology of mental illness -- 1.3 Neurodevelopmental theories -- Neurons and neurotransmitters -- 1.4 Clinical decision making in practice, and medicine management and optimisation -- Psychosocial interventions in mental health settings -- 2 Drugs used in psychoses -- 2.1 Introduction -- Severe mental illness -- Schizophrenia
505	8		_a2.2 Mechanism of action -- Biochemical theories -- Glutamate hypothesis -- Dopamine hypothesis -- Typical antipsychotics -- Atypical antipsychotics -- 2.3 Dose and administration -- Rapid tranquillisation -- Non-restrictive interventions -- Antipsychotic drugs in depot preparation -- Cytochrome P450 drug-metabolising enzymes interaction with psychotropics -- 2.4 Adverse effects and management -- Extrapyramidal side effects -- Dystonia -- Management of dystonia -- Akathisia -- Management of akathisia -- Drug-induced parkinsonism -- Management of drug-induced parkinsonism -- Tardive dyskinesia
505	8		_aManagement of tardive dyskinesia -- Anticholinergic drugs -- Non-extrapyramidal adverse effects of antipsychotic drugs -- Muscarinic 1 receptor block -- Cardiovascular effects -- Weight gain and mental illness -- Gender -- Socioeconomic status and level of education -- Age -- Other contributing factors to weight gain in people with mental illness -- Metabolic syndrome -- Glycaemic abnormalities as a consequence of treatment and mental illness -- Endocrine adverse effects -- Allergic and dermatological effects -- Haematological adverse effects -- Obligatory monitoring for clozapine therapy
505	8		_aClozapine alert -- Other adverse effects of clozapine -- Neuroleptic malignant syndrome -- Improving physical health needs in SMI: best practice monitoring -- Behavioural change initiatives alongside routine physical health monitoring -- Lester Cardiometabolic Tool -- National Early Warning Score 2 (NEWS 2) -- QRISK®3 -- 2.5 Medication adherence in mental health settings -- 3 Drugs used in depression -- 3.1 Introduction -- ICD-11: key changes in relation to depression diagnostic criteria -- Screening for depression and anxiety in primary care settings -- Co-morbid psychiatric presentations
505	8		_aKey points about assessment and management of symptoms of depression and anxiety in primary care -- 3.2 Mechanism of action -- Monoamine theory of depression -- 3.3 Dose and administration -- 3.4 Adverse effects and management -- Tricyclic antidepressants -- Adverse effects and management -- Selective serotonin reuptake inhibitors -- Adverse effects and management -- Serotonin-noradrenaline reuptake inhibitors -- Adverse effects and management -- Tetracyclic (noradrenergic and specific serotonergic antidepressants) -- Adverse effects and management -- Aminoketone (bupropion)
520			_aAn updated and revised edition of this accessible best-selling text suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes.
650		0	_aPsychopharmacology _vHandbooks, manuals, etc.
830		0	_aNursing.
856	4	0	_3EBSCOhost (requires login) _uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3028130
938			_aEBSCOhost _bEBSC _n3028130
938			_aProQuest Ebook Central _bEBLB _nEBL6720711
942			_cCF
994			_a92 _bN$T
999			_c2023 _d2023